Actelion Plans to Cut 135 Jobs, Refocus Research Effort

Actelion Ltd. plans to cut 135 jobs and refocus research on rare diseases and specialty pharmaceuticals as sales decline for the company’s best-selling product, the Tracleer blood-pressure drug.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.